Trauma and PTSD: Symptoms, Causes, and How It's Treated

Most people who live through something frightening do not develop a lasting disorder, but for a significant minority the aftermath of a traumatic event can become a clinical condition called post-traumatic stress disorder. A cross-national survey of 71,083 adults across 26 countries, published in Psychological Medicine by Koenen et al. (2017), found a lifetime PTSD prevalence of 3.9% in the general population and 5.6% among those who had experienced a traumatic event. That gap between exposure and diagnosis matters: trauma is common; PTSD is a specific, treatable condition, not an inevitable outcome.

What trauma does, and how PTSD develops

Trauma refers to the psychological impact of an event that overwhelms a person’s capacity to cope, rather than to the event itself. Road accidents, physical assault, medical emergencies, natural disasters, and witnessing violence can all be traumatic, as can more sustained experiences such as domestic abuse or childhood neglect. Not every difficult experience meets the clinical threshold, and individual responses to the same event vary considerably depending on prior history, social support, and biological factors.

When the nervous system processes a frightening event normally, distress typically fades over days or weeks. In PTSD, that processing stalls. Intrusive memories, physical arousal, and a strong drive to avoid reminders persist long after the danger has passed. The result is a pattern in which memories of the event feel current, threatening, and disorganising rather than filed as part of the past. PTSD can follow a single incident or emerge after months of repeated exposure. Symptoms often begin within weeks of the event, but delayed presentations, where full criteria are not met until six months or more after the trauma, are also well documented.

Risk factors associated with higher rates of PTSD include the severity and proximity of the trauma, prior mental health difficulties, limited social support, and, for some trauma types, being female. Protective factors include strong social networks, access to prompt support, and the absence of ongoing threat. These factors affect the probability of developing PTSD, but none is deterministic: PTSD can develop in people with strong protective factors, and it does not develop in many people who lack them.

Symptoms and how PTSD is diagnosed in 2026

Clinicians diagnosing PTSD in adults look for four clusters of symptoms that persist for more than one month and cause significant distress or impairment.

The first cluster is re-experiencing: intrusive memories, nightmares, or flashbacks in which the person feels as though the event is happening again, triggered by reminders or arising unpredictably. These are not simply bad memories but vivid, distressing re-activations that can be accompanied by physical arousal.

The second cluster is avoidance: deliberate efforts to stay away from thoughts, feelings, or external reminders connected to the trauma. This can narrow a person’s world considerably, leading them to avoid places, activities, or conversations that carry even an indirect association.

The third cluster covers negative changes in thinking and mood: persistent negative beliefs about oneself or the world, distorted blame, emotional numbing, reduced interest in activities, and difficulty experiencing positive emotions.

The fourth is changes in arousal and reactivity: an elevated state of alertness that was adaptive during the danger but becomes exhausting when sustained. Sleep difficulty, irritability, difficulty concentrating, and an exaggerated startle response are common.

Both the DSM-5-TR and the ICD-11 require these symptoms to cause clinically significant impairment, distinguishing PTSD from the normal stress responses that most trauma-exposed people experience and recover from without treatment. Brewin et al. (2017) reviewed the evidence for ICD-11’s revised diagnostic structure and concluded that the proposed criteria identify a distinct, impaired group, while being somewhat narrower than DSM-5, meaning the two systems do not always produce identical diagnoses for the same person.

Complex PTSD: when trauma is prolonged or repeated

The ICD-11 introduced a separate diagnostic category alongside PTSD: complex PTSD, which captures the distinctive sequelae of prolonged or repeated trauma, particularly when it occurred in contexts from which escape was difficult, such as childhood abuse, trafficking, or sustained domestic violence.

Complex PTSD shares the three core PTSD symptom clusters but adds three further domains: persistent difficulties with emotional regulation, a pervasive negative sense of self, and problems in maintaining relationships. This additional layer reflects what clinicians have long observed in people whose trauma was not a single event but a sustained feature of their early life or close relationships.

Brewin et al. (2017) concluded that the evidence supports the ICD-11 distinction, with complex PTSD identifying a group that has more often experienced multiple and sustained traumas and shows greater functional impairment. Redican et al. (2022) found that in a trauma-exposed population of young people in Northern Ireland, more participants met criteria for complex PTSD than for PTSD alone, suggesting the condition may be underrecognised, particularly in younger groups.

Treatment for complex PTSD generally follows a phased approach. Initial work focuses on stabilisation, which means building sufficient emotional regulation and safety before processing traumatic memories. Only when a stable foundation is established do most clinicians move to trauma-focused work. This sequence is not universal, and some evidence supports flexible integration of processing and stabilisation, but the phased model remains the dominant clinical framework.

Evidence-based treatments: trauma-focused therapy and EMDR

The strongest evidence base for PTSD supports trauma-focused psychological therapies, which engage directly with traumatic memories rather than working around them. NICE guideline NG116, first issued in 2018 and reviewed in 2025, recommends individual trauma-focused CBT as the primary intervention for adults presenting more than one month after a traumatic event. EMDR is recommended as a first-line option for adults presenting more than three months post-trauma with a confirmed PTSD diagnosis.

Trauma-focused CBT typically involves psychoeducation about trauma responses, graduated exposure to feared memories and situations, and direct work on trauma-related beliefs. NICE NG116 specifies that this should ordinarily be provided over eight to twelve sessions with a trained practitioner.

EMDR follows a structured eight-phase protocol in which the patient holds a distressing memory in mind while tracking bilateral stimulation, most commonly the therapist’s moving finger. The mechanism remains a subject of research, but the treatment’s efficacy is not contingent on resolving that question. A 2013 Cochrane review by Bisson et al., covering 70 randomised trials involving 4,761 participants, found that both individual trauma-focused CBT and EMDR outperformed waitlist and usual care conditions in reducing PTSD symptoms, with no statistically significant difference between the two approaches at post-treatment.

A 2023 network meta-analysis by Hoppen et al., drawing on 157 randomised controlled trials involving 11,565 participants, confirmed that trauma-focused interventions show modest but consistent superiority over non-trauma-focused approaches, with trauma-focused CBT demonstrating the highest overall efficacy across short-, mid-, and long-term follow-up. A 2023 systematic review and meta-analysis by Rasines-Laudes and Serrano-Pintado, examining 18 randomised trials of EMDR, found small but positive effect sizes for reductions in PTSD, anxiety, and depression symptoms compared to control conditions, though the authors noted methodological variability across included studies and cautioned against over-extrapolation to all clinical settings.

The ISTSS guidelines, developed through a systematic review of 361 randomised controlled trials and 208 meta-analyses, produced eight strong-evidence recommendations, with trauma-focused therapies prominent among them.

Medication is not a first-line treatment for PTSD in the NICE framework. Certain antidepressants, particularly SSRIs and venlafaxine, may be considered for adults who decline psychological treatment or for whom it has not produced sufficient benefit, but the evidence base is weaker than that for psychological therapies.

Starting treatment and what recovery looks like

Seeking help for PTSD is often the hardest step. Many people with the condition live with it for years without a diagnosis, partly because avoidance of trauma-related thoughts extends to avoiding conversations about what happened. There is no clinical advantage to waiting: early treatment is associated with better outcomes, and delayed presentations are still highly treatable.

First contact with a mental health professional typically involves a structured assessment to clarify the diagnosis, identify any co-occurring conditions such as depression or problematic alcohol use, and determine which treatment approach fits the person’s circumstances. For complex trauma presentations, the assessment process may itself take several sessions.

Recovery is not uniform. A substantial proportion of people who complete a full course of trauma-focused CBT or EMDR no longer meet diagnostic criteria for PTSD by the end of treatment, and gains are generally maintained at follow-up. Bisson et al. (2013) noted that improvement was evident and durable in the majority of treated patients across the trials they reviewed. Some people, however, respond only partially, require further treatment, or have needs that a standard course of therapy does not fully address. This is not a failure of effort; it reflects the complexity of trauma and the variability of individual response.

Support from trusted people in a person’s life can aid recovery, and clinicians often involve the wider support network where the person wants this. Physical activity, regular sleep, and limiting substances that temporarily suppress but ultimately worsen anxiety symptoms are commonly recommended alongside formal therapy, though these are adjuncts rather than treatments in their own right.

Recovery from PTSD is possible. It is slower and more effortful than many people hope, and it rarely follows a straight line, but the evidence base for the available treatments is among the strongest in all of mental health.

Frequently asked questions

What is the difference between trauma and PTSD?

Trauma describes the psychological experience of an overwhelming event, the impact it has on a person’s sense of safety, their beliefs, and their capacity to cope. PTSD is a specific clinical disorder that can develop in the weeks and months that follow a traumatic experience. Most people who live through a traumatic event do not develop PTSD: symptoms such as intrusive memories, disturbed sleep, and heightened alertness are normal in the immediate aftermath and typically resolve. PTSD is diagnosed when these symptoms persist beyond one month, cause significant impairment, and meet the full diagnostic criteria. The distinction matters because it determines whether watchful waiting, brief psychological support, or a formal trauma-focused treatment is indicated.

What is complex PTSD and how does it differ from PTSD?

Complex PTSD is recognised in the ICD-11 as a distinct condition that shares the core PTSD symptom clusters but adds three additional domains: severe difficulties with emotional regulation, a persistently negative and damaged sense of self, and significant problems in forming or maintaining relationships. It tends to follow prolonged or repeated trauma, particularly in contexts where the person lacked control or the ability to escape, such as sustained childhood abuse or trafficking. Treatment generally involves a phased approach, stabilising emotional regulation before moving to direct work on traumatic memories, though the precise sequence is adapted to the individual.

Does EMDR actually work, and how?

EMDR has a well-established evidence base for PTSD. NICE NG116 recommends it as a first-line treatment for adults presenting more than three months after a traumatic event, and the Cochrane review by Bisson et al. (2013) found EMDR superior to waitlist control across 70 trials. The precise mechanism by which bilateral stimulation aids processing of traumatic memory remains an active area of research, and the specific contribution of the eye-movement component continues to be studied. The clinical evidence for efficacy does not depend on resolving this question: what the research shows is that people treated with EMDR experience significant reductions in PTSD symptoms and that these gains are maintained.

How long does PTSD treatment usually take?

NICE NG116 specifies that trauma-focused CBT should ordinarily be provided over eight to twelve sessions for adults with PTSD following a single traumatic event. EMDR typically follows a comparable timeframe, though some presentations, particularly those involving multiple traumas or complex PTSD, may require a longer course. Treatment for complex PTSD, with its phased approach and additional stabilisation work, tends to be extended considerably, sometimes to several months or longer. These are averages; some people respond more quickly, others need more time, and partial responders may benefit from a further course or a different approach.

Can PTSD develop years after the traumatic event?

Yes. While PTSD most often begins within weeks or months of a traumatic event, delayed-onset presentations, defined in the DSM-5-TR as meeting full criteria for the first time six or more months after the event, do occur. These can involve symptoms that were present but sub-threshold at an earlier point, or a re-emergence or escalation of symptoms triggered by a later life event such as a bereavement or health crisis that resonates with the original trauma. Delayed PTSD responds to the same treatments as earlier presentations.

Is medication useful for PTSD?

Medication is not recommended as a first-line treatment for PTSD in the UK clinical guidelines. Psychological therapies, particularly trauma-focused CBT and EMDR, have a stronger evidence base. Where someone is unable or unwilling to engage with psychological treatment, or where an initial course of therapy has not achieved sufficient improvement, certain antidepressants, especially SSRIs such as sertraline or paroxetine, or venlafaxine, may be considered. Sleep disruption, depression, and anxiety that co-occur with PTSD are sometimes addressed with medication alongside psychological treatment, but medication alone does not address the underlying trauma processing difficulties. Any decision about medication should be made with a prescribing clinician who is familiar with the person’s full clinical picture.

For further reading on related topics, explore the topics page, visit our anxiety hub, or read the depression overview.